SOURCE: Duravest, Inc.

June 23, 2006 13:24 ET

Duravest Updates Investment Community With Interview

CHICAGO, IL -- (MARKET WIRE) -- June 23, 2006 -- Dr. Ogan Gurel, Chief Executive Officer of Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV), updated the investment community in a recent interview with

Duravest is a unique company that is leading the way in strategically acquiring, developing, and accelerating next-generation convergent medical technology firms. In the company's interview with, Dr. Gurel provided updates on the following topics:

--  Existing trends in the medical device market, particularly related to
    the growth and demand for convergent medical technologies as well as
    greater levels of safety.
--  The company's Estracure subsidiary, which is developing a next-
    generation drug-eluting stent with the renowned Montreal Heart Institute.
--  The company's strategy going forward, including the potential for a
    listing on a more liquid exchange.
To hear the interview in its entirety, and to read more about Duravest, visit io/audio.asp?symbol=DUVT&id=2232. Interviews require free registration on

In addition to his position as CEO of Duravest, Inc., Dr. Gurel is also President-elect of the Chicago Health Executives Forum, a prominent professional organization dedicated to health care executives in metropolitan Chicago. He presents frequently on topics involving future trends in medicine with a particular emphasis on emerging technologies. For example, Dr. Gurel will be speaking at a number of upcoming events:

--  "Evaluation and assessment of advances and trends in technologies in
    healthcare" at the Illinois Institute of Technology Center for the
    Management of Medical Technology (CMMT) Hospital of the Future '06
    conference in Chicago on August 17th - 18th.
--  "Future Trends in Technology Impacting Cancer Care" as a keynote
    presenter at the 6th annual National Conference on Comprehensive Cancer
    Programs and Services Care Centers in Palo Alto, CA on September 19-20th.
--  "Medical Nanotechnology: Business Models, Financing and Valuation" as
    a keynote speaker at the Investing in Medical NanoTechnologies, Conference
    and Exhibition 2006, 13-14 December in London.
He is also the acting CEO of PST, GmbH, an expansion stage Duravest subsidiary that develops and markets non-invasive therapy solutions for osteoarthritis, osteoporosis and sports-related injuries.

About Duravest, Inc.

Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV) is a publicly traded holding company that initiates and develops strategic investments in next-generation convergent medical technologies. Duravest currently has two subsidiaries: Estracure, Inc. -- based in Montreal, Canada -- which is developing a next-generation coronary stent based on proprietary 17-beta-estradiol and PST, GmbH -- based in Munich, Germany -- which currently markets patented bio-magnetic therapies for orthopedic conditions and their associated pain management. Estracure is developing a next-generation stent that specifically addresses potential safety issues with the current generation of coronary drug-eluting stents and thus represents not just a potential niche player but a replacement product in the market. The active agent in the Estracure stent -- 17-beta-estradiol -- has a pro-healing effect (by stimulating re-endothelialization) that has been documented by extensive in vitro and in vivo studies. The Duravest strategy encompasses three themes: (1) rapid commercialization of next-generation medical technologies by providing its portfolio of subsidiaries with financial, operational and scientific support, (2) prioritization of safety and (3) development of convergent medical technologies that span the traditional categories of biotechnology, pharmaceuticals, healthcare IT and medical devices.

About is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. The company has received one million four hundred thousand restricted shares of AHDG from Atlantis Holdings Corp. for media and advertising services. For a complete list of our advertisers, and advertising relationships, visit

Safe Harbor Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward-looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.

Contact Information